Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2026

Genmab — Februar 2026

Planlagt Fastgjort Låst Flyttet Genmab
385 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #343

    😉 the new GEN1106 also already starts recruiting

    1 Reply Last reply
    0
    • concilladoC Offline
      concilladoC Offline
      concillado
      wrote on sidst redigeret af
      #344

      Så redder aktietilbagekøbsprogrammet lige dagskursen igen kl. 15:25 😉

      1 Reply Last reply
      0
      • B Offline
        B Offline
        BuyLow
        wrote on sidst redigeret af
        #345

        EL re epkinly/Tivdak sales outlook. Yes, that didn't make sense to me either. In Presentation on page 7-8-9 the numbers it states Epkinly alone was 468 +67%, Epco, Tivdak Combined 632 +54%, Not sure how we get only 11,5% growth next year

        1 Reply Last reply
        0
        • W Offline
          W Offline
          w
          wrote on sidst redigeret af
          #346

          Er det
          fordi 3. linie i epco og 2. Line tivdak ikke har flere patienter

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #347

            yes, that is the reason why growth will slow, but from 67% to 11.5% is a big drop, also given the approval of 2nd line FL and the constant focus on community centers with the subcutaneaous formulation, where i had hoped additional growth could come from

            1 Reply Last reply
            0
            • StockBullS Offline
              StockBullS Offline
              StockBull
              wrote on sidst redigeret af
              #348

              Marts er ofte en relativt sløv periode. Jeg holder derfor tørt krudt på sidelinjen og venter på et potentielt pull-back (f.eks. mod 1.780–1.820 eller RSI <27–30 på daily), før jeg overvejer yderligere supplering. Det giver bedre risk/reward før eventuel opgang i april/maj.

              1 Reply Last reply
              0
              • StockBullS Offline
                StockBullS Offline
                StockBull
                wrote on sidst redigeret af
                #349

                skulle være 1.720–1.780

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #350

                  Tepkinly – Epcoritamab - on the EMA CHMP agenda: Scope: Extension of indication to include in combination with rituximab and lenalidomide treatment of patients with relapsed/refractory follicular lymphoma (FL) for Tepkinly https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-23-26-february-2026_en.pdf

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #351

                    NICE Recommends TEPKINLY®▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy https://www.abbvie.co.uk/media/nice-recommends-tepkinly-epcoritamab-a-subcutaneous-bispecific-antibody-for-adults-with-relapsed-refractory-follicular-lymphoma-after-two-or-more-lines-of-systemic-therapy.html

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #352

                      so the UK is behind, but the EU extension mentioned above is also under review in UK for publication date Sep26

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #353

                        RAINFOL-02 goes to Active, not recruiting https://clinicaltrials.gov/study/NCT06619236?tab=history&a=16&b=17#version-content-panel

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #354

                          innovaTV 301 Completed

                          1 Reply Last reply
                          0
                          • R Offline
                            R Offline
                            Raun
                            wrote on sidst redigeret af
                            #355

                            Genmab Buyback And Abkinley Approval Reframe Growth And Risk Balance https://finance.yahoo.com/news/genmab-buyback-abkinley-approval-reframe-050838816.html

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              bikube
                              wrote on sidst redigeret af
                              #356

                              Godt at få deres syn på sagen også.

                              1 Reply Last reply
                              0
                              • N Offline
                                N Offline
                                npo
                                wrote on sidst redigeret af
                                #357

                                @Raun 17:07 - tak for link/
                                heads-up

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #358

                                  Godmorgen 🙂

                                  1 Reply Last reply
                                  0
                                  • L Offline
                                    L Offline
                                    LP90
                                    wrote on sidst redigeret af
                                    #359

                                    Godmorgen 🙂

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      bibob
                                      wrote on sidst redigeret af
                                      #360

                                      God morgen. 🙂

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #361

                                        Link Preview Image
                                        Genmab trak stikket på blockbusterdrøm – nu viser andre selskaber interesse

                                        Genmab-topchef er overbevist om, at det tidligere spået blockbuster-håb acasunlimab ville have nået markedet, men konkurrencen gjorde det nødvendigt at droppe udviklingen, siger Jan van de Winkel.

                                        favicon

                                        (medwatch.dk)

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #362

                                          Ville da være dejligt hvis Genmab kunne skippe acasunlimab videre til et andet selskab

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper